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Abstract 23 
Background 24 
Process evaluations are increasingly conducted within pragmatic randomised controlled trials (RCTs) 25 
of health services interventions and provide vital information to enhance understanding of RCT 26 
findings.  However, issues pertaining to process evaluation in this specific context have been little 27 
discussed.  We aimed to describe the frequency, characteristics, labelling, value, practical conduct 28 
issues, and accessibility of published process evaluations within pragmatic RCTs in health services 29 
research. 30 
Methods 31 
We used a 2-phase systematic search process to 1) identify an index sample of journal articles 32 
reporting primary outcome results of pragmatic RCTs published in 2015, then 2) identify all 33 
associated publications.  We used an operational definition of process evaluation based on the 34 
Medical Research Council’s process evaluation framework to identify both process evaluations 35 
reported separately, and process data reported in the trial results papers.  We extracted and 36 
analysed quantitative and qualitative data to answer review objectives. 37 
Results 38 
From an index sample of 31 pragmatic RCTs we identified 17 separate process evaluation studies.  39 
These had varied characteristics and only three were labelled ‘process evaluation’.  Each of the 31 40 
trial results papers also reported process data, with a median of five different process evaluation 41 
components per trial.  Reported barriers and facilitators related to real-world collection of process 42 
data, recruitment of participants to process evaluations, and health services research regulations.  43 
We synthesised a wide range of reported benefits of process evaluations to interventions, trials, and 44 
wider knowledge.  Visibility was often poor, with 13/17 process evaluations not mentioned in the 45 
trial results paper, and 12/16 process evaluation journal articles not appearing in the trial registry.   46 
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Conclusions  47 
In our sample of reviewed pragmatic RCTs the meaning of the label ‘process evaluation’ appears 48 
uncertain, and the scope and significance of the term warrant further research and clarification.  49 
Although there were many ways in which the process evaluations added value, they often had poor 50 
visibility.  Our findings suggest approaches that could enhance the planning and utility of process 51 
evaluations in the context of pragmatic RCTs.   52 
Registration 53 
Not applicable for PROSPERO registration 54 
Keywords 55 
Process evaluation, pragmatic randomised controlled trials, health services research 56 
 57 
Background  58 
There are increasing calls for process evaluations alongside outcome evaluations of complex 59 
healthcare interventions (1-3).  Defining features of ‘complex interventions’ include having multiple 60 
interacting components, addressing multiple outcomes, and targeting different levels of change 61 
within complex systems (4).  Process evaluations increase understanding of complex healthcare 62 
interventions by studying aspects of implementation, mechanisms of impact, and context (4).  They 63 
may thus shed light on the ‘black box’ of complex interventions and provide information to interpret 64 
outcome results and aid implementation into practice (4, 5).  There has been similar increasing 65 
interest in the use of pragmatic randomised controlled trials (RCTs) to evaluate the outcomes of 66 
complex healthcare interventions (1, 6) .  Pragmatic RCTs, in contrast to explanatory RCTs, aim to 67 
conduct ‘real-world’ evaluation of interventions, with findings that have enhanced generalisability to 68 
real world clinical practice (6).   69 
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Masterson-Algar et al. (7) highlight the importance of tailoring process evaluation guidance to the 70 
context in which it will be used, and accordingly this review aims to address gaps in knowledge 71 
about process evaluation conduct in the context of pragmatic RCTs of health services interventions.  72 
The UK Medical Research Council (MRC) published comprehensive guidance for designing and 73 
conducting process evaluations of complex interventions in 2014 (4), following earlier process 74 
evaluation frameworks by other authors (5, 8, 9).  However, apart from Grant et al.’s framework (5), 75 
these were developed primarily for public health research.  Although being described as applicable 76 
to health services research, many of the examples in the MRC’s guidance (4) are from a public health 77 
perspective.  It is therefore useful to review process evaluation conduct in health services settings as 78 
these are likely to present some unique challenges.  The few published systematic reviews of process 79 
evaluation methodology focus on specific fields of clinical practice (10-15) rather than outcome 80 
evaluation methods.  The pragmatic RCT method is not explicitly addressed in existing process 81 
evaluation guidance, although some pertinent methodological issues are discussed, for example 82 
avoiding Hawthorne effects from patients participating in process evaluation interviews (4).  83 
Nonetheless, concerns have been raised relating to pragmatic RCTs, such as the potential variability 84 
of usual care within control groups, and the potential impact of interventions beyond intervention 85 
recipients, such as to carers and family members (16).  Process evaluations present opportunities to 86 
examine and address such issues. 87 
This review aims to provide insight into the state of process evaluation in the context of pragmatic 88 
RCTs in health services research, along with the reported value, barriers, and facilitators to 89 
conducting them.  We also examine two issues identified as problematic, both from our own 90 
experience and within the process evaluation literature.  Firstly, we investigate labelling, as the label 91 
‘process evaluation’ has been applied to many types of study (4), and previous reviews noted 92 
inconsistent use of the term (5, 10).  We have also anecdotally encountered confusion and multiple 93 
interpretations of the meaning of the label.  Secondly we examine accessibility as suboptimal 94 
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reporting has been highlighted, such as time delay and poor linkages between trial and process 95 
evaluation results publications (4).    96 
Our aims were, within a systematically identified sample of published pragmatic health services 97 
research RCTs, to: 98 
1. Describe the process data reported in trial results papers  99 
2. Describe the frequency of separate process evaluation publications  100 
3. Describe use of the label ‘process evaluation’ 101 
4. Describe the characteristics of process evaluations 102 
5. Synthesise reported practical barriers and facilitators to process evaluation conduct   103 
6. Synthesise the reported values of the process evaluations 104 
7. Describe the accessibility of process evaluation results 105 
 106 
Methods 107 
Similar to previous systematic reviews of process evaluations (11, 12) we used a 2-phase search 108 
process.  We firstly systematically identified an index sample of journal articles reporting the primary 109 
outcome results of pragmatic RCTs evaluating health services interventions (hereafter referred to as 110 
‘trial results papers’), then systematically searched for all associated publications.  Using an 111 
operational definition of process evaluation based on the MRC’s framework (4) we then identified 112 
the process evaluations reported in associated publications, regardless of how they were labelled.  113 
We also identified any process data reported in index trial results papers which mapped to MRC 114 
process evaluation components.  Figure 1 illustrates the methods and table 1 shows the MRC 115 
process evaluation components. 116 
Figure 1: Methods overview 117 
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Table 1: MRC process evaluation components (adapted from (4), with definitions in italics where 118 
provided in original) 119 
CONTEXT 
Causal mechanisms present 
within the context that act to 
maintain the status quo, or 
enhance effects 
 
Contextual factors that shape 
theory of how the intervention 
works 
 
Contextual moderators 
Shape, and may be shaped by, 
implementation, intervention 
mechanisms, and outcomes 
 
IMPLEMENTATION 
Dose  
How much intervention is 
delivered 
 
Fidelity 
The consistency of what is 
implemented with the planned 
intervention 
 
Adaptations 
Alterations made to an 
intervention in order to 
achieve better contextual fit 
 
How delivery is achieved 
The structures, resources and 
mechanisms through which 
delivery is achieved 
 
Reach 
Extent to which target 
audience comes into contact 
with intervention 
 
 
MECHANISMS OF IMPACT 
Mediators  
Intermediate processes which 
explain subsequent changes in 
outcome 
 
Participant responses 
How participants interact with 
a complex intervention 
 
Unanticipated pathways and 
consequences 
 
 120 
Search strategy, inclusion and exclusion criteria 121 
In the first search phase we systematically identified an index sample of pragmatic RCTs. We limited 122 
the search to a single year, 2015, (selected to allow time for related publications to appear) and to 123 
Medline Core Clinical Journals to provide a feasible number of papers.  We searched Medline (Ovid), 124 
the full search strategy is given in additional file 1. 125 
Phase 1 inclusion criteria (PICOS) 126 
 Population: any 127 
 Intervention: any delivered by a health service 128 
 Comparator: any 129 
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 Outcome: any 130 
 Study: pragmatic randomised controlled trial (defined as use of the word ‘pragmatic’ to 131 
describe the RCT in the title or abstract) 132 
Phase 1 exclusion criteria 133 
1. Papers not reporting the primary trial outcome  134 
2. RCTs labelled as pilot, feasibility, or implementation studies.    135 
3. Trials of health interventions not delivered within health services, for example by charities 136 
In phase 1, two reviewers (CF and IS) independently screened titles and abstracts against the 137 
inclusion and exclusion criteria, obtaining full-texts as necessary.  Any disagreements were discussed 138 
with ST and HP to reach a final decision on inclusion.   139 
In phase 2 (see figure 1) citation searches for each trial results paper were conducted using both 140 
Web of Science (Clarivate Analytics) and Google Scholar.  Corresponding authors were sent one 141 
reminder if we received no reply following the first contact.  The searches were originally conducted, 142 
and authors contacted, in March and April 2018.  Search phase 2 was updated in December 2019 143 
apart from author contact. 144 
We used an operational definition of ‘process evaluation’ to identify papers for inclusion regardless 145 
of how they were labelled by the study authors.   As shown in figure 1, included studies investigated 146 
one or more MRC process evaluation components and (to distinguish them from trial secondary 147 
analyses or sub-studies) were aimed at increasing understanding of the intervention or trial.  One 148 
reviewer (CF) screened all publications and discussed all considered to possibly be process 149 
evaluations with HP and ST in a consensus meeting to agree the final sample of process evaluations. 150 
Several index trials were funded by the UK National Institute for Health Research’s Health 151 
Technology Assessment (HTA) programme.  This programme requires results to be published as a 152 
monograph in the Health Technology Assessment journal, additional to any other journal 153 
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publications.  We therefore reviewed the full texts of all HTA monographs to check for process 154 
evaluation results. 155 
Data extraction and analysis 156 
As this was a review of methodology rather than findings, we did not conduct any appraisal of 157 
quality of the included process evaluation studies.  We extracted quantitative data to an Excel 158 
database and conducted descriptive analysis using SPSS v25.  We extracted qualitative data as 159 
sections of text from PDFs of publications and used NVivo v11 for data management and to aid 160 
thematic analysis. 161 
Where the methods or results from a single trial or process evaluation were reported in more than 162 
one publication (e.g. HTA monograph and separate journal paper) we extracted all available data 163 
from all publications but treated the publications as a single case.  CF extracted and analysed all data 164 
independently, apart from the MRC process evaluation components as detailed below. 165 
Data extracted from the trial results papers 166 
We extracted descriptors of all trials, and the data fields and their operationalisation are shown in 167 
additional file 2.  We mapped data items reported in the results sections to the MRC process 168 
evaluation framework (4) (see table 1) to identify process data within the trial results papers.  For 169 
example, a trial flow diagram (process data item) mapped to the process evaluation component 170 
‘reach’.  For each trial we recorded whether each process evaluation component was reported in the 171 
trial results paper at least once.  We piloted this process, and as the MRC guidance does not provide 172 
clear definitions for some components, we made a list of the types of data which mapped to each 173 
component (for example subgroup analyses mapped to ‘contextual moderators’).  Three reviewers 174 
(CF, GF, and IS) independently extracted data from the first three trials, compared results, and 175 
agreed initial mappings.  We used these to extract data from four further trials, and again compared 176 
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and discuss findings.  CF then extracted data for the remaining trials, discussing any new mappings 177 
or uncertainties with the other authors.   178 
Data extracted from process evaluation publications 179 
Table 2 shows the outcomes extracted for each process evaluation publication.  O’Cathain et al. (17) 180 
noted that the value of qualitative research within RCTs is often not clearly articulated in 181 
publications, and we noted the same during scoping this review.  We therefore operationalised 182 
‘reported value’ as any reported rationales for undertaking a process evaluation, or any reported 183 
implications of having undertaken it or of its findings.  This allowed us to capture any anticipated or 184 
observed benefits of the process evaluation or use of the knowledge it produced. 185 
Table 2: Data outcomes for process evaluation publications 186 
Review objective  Type of data Outcomes 
Labelling Quantitative  Use of label ‘process evaluation’ 
anywhere in the set of papers for the 
trial 
 Use of keyword ‘process evaluation’ 
for indexing  
Characteristics Quantitative  Process evaluation components 
(mapped from aims and qualitative 
findings) 
 Whether processes related to the 
intervention or trial 
 Methodology  
 Data collection method 
Reported barriers and 
facilitators 
Qualitative  Practical issues relating to designing or 
operationalising the process 
evaluation 
Reported value Qualitative  Reported rationales for undertaking, 
or implications of the process 
evaluation 
Accessibility Quantitative  Publishing journal 
 Time to publication from trial results 
paper 
 Search method required to locate 
paper 
 Mention of the process evaluation in 
trial results paper 
 Where in paper the trial first named or 
referenced 
10 
 
 Inclusion in trial registry  
 187 
A completed PRISMA checklist is in additional file 3  188 
 189 
Results 190 
Figure 2 shows the results of search phases 1 and 2.  The first search phase yielded 31 journal 191 
articles reporting primary outcome results from pragmatic RCTs, and the second phase located 133 192 
associated publications.  We categorised 21 of these 133 associated publications as process 193 
evaluation results.  These covered 17 separate process evaluation studies, as some were published 194 
in more than one paper. 195 
Figure 2: Adapted PRISMA flow diagram (18) 196 
[footnote for figure 2] *searches conducted in order stated and each record included only under 197 
search method first found 198 
Characteristics of the sample of pragmatic RCTs 199 
The sample of pragmatic RCTs (n=31) was highly variable in terms of intervention and trial 200 
characteristics (see additional file 4 for details of the RCTs).  They covered 20 different clinical 201 
specialties and 17 different combinations of professionals involved in intervention delivery.  Most 202 
interventions (28/31) were received by patients only, with the remainder directed at staff or staff 203 
and patients.  Table 3 summarises further characteristics of the included trials. 204 
Table 3: Characteristics of the index sample of pragmatic RCTs 205 
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Randomisation level 
Individual 
Cluster 
 
Design 
2-arm 
Non-inferiority (2-arm) 
3-arm 
Crossover 
Stepped-wedge 
 
Primary outcome result 
No evidence of effect 
Evidence of effect 
Non-inferiority trial 
Unclear 
 
Funder 
Public 
Multiple funders 
Charity 
Independent Organisation 
Not reported 
 
Type of intervention 
Pharmacological treatment strategy 
Clinical procedure 
Therapy intervention 
Clinical treatment strategy 
Model of care provision 
Reminder system 
Health promotion 
Medical device 
 
 
 
25 
6 
 
 
22 
4 
3 
1 
1 
 
 
15 
11 
4 
1 
 
 
25 
3  
1 
1 
1 
 
 
9 
4 
4 
3 
3 
3 
3 
2 
Comparator 
Usual care 
Other intervention(s) 
Stepped-wedge control period 
Comparing two settings 
Comparing two deliverers 
No intervention 
Sham clinical procedure 
 
Publishing journal 
British Medical Journal  
Lancet 
JAMA 
Canadian Medical Association Journal 
JAMA Pediatrics 
Critical Care Medicine 
Gut 
JAMA Internal Medicine 
JAMA Psychiatry 
Journal of Allergy and Clinical Immunology 
New England Journal of Medicine 
Nursing Research 
The American Journal of Psychiatry 
 
Country 
UK 
USA 
Australia 
Netherlands 
Brazil 
Canada 
France 
France, Belgium and Switzerland 
Hong Kong 
North America* 
 
15 
10 
2 
1 
1 
1 
1 
 
 
7 
7 
5 
2 
2 
1 
1 
1 
1 
1 
1 
1 
1 
 
 
12 
8 
3 
2 
1 
1 
1 
1 
1 
1 
*Countries not specified in original article 206 
Process evaluations 207 
Twelve of the 31 pragmatic RCTs had at least one associated publication which we classified as 208 
reporting process evaluation results.  We identified 17 distinct process evaluation studies, with two 209 
trials (19, 20) having three process evaluations and one trial (21) having two process evaluations.  210 
Although it is likely that these multiple process evaluation studies in the same trials formed part of 211 
one overall process evaluation, as each was presented as a distinct study, we extracted data from 212 
each individually.  The 17 process evaluation studies were published across 21 publications, as some 213 
were published in both a journal article and HTA monograph.   214 
The 17 process evaluation studies are listed in table 4. 215 
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Table 4: Included process evaluation studies [multi-page table, please find at end of this document] 216 
 217 
Labelling  218 
In the trial results papers the label ‘process evaluation’ was never used to describe the process data.  219 
Five trials (19, 43-46) used variations of the labels ‘process outcome’ or ‘process measure’ for some 220 
data, although this use was infrequent and inconsistent.   221 
Only three of the 17 studies we classified as process evaluations were labelled as process 222 
evaluations (30, 31, 33, 34).  One further study was not explicitly labelled as a process evaluation but 223 
this was implied as the MRC process evaluation guidance was cited as a rationale for undertaking it 224 
(28).  Only one of the three studies labelled as ‘process evaluation’ was clearly labelled as such in the 225 
article title (31).  One was described as ‘informing a process evaluation’ in the main article text (30).  226 
The other was referred to as a process evaluation by the trial results paper (47), but not labelled as 227 
such in the journal article (33) or HTA monograph (34) reporting it.   228 
Notably, one trial (19) had three qualitative studies published in the same journal: a qualitative 229 
interview study labelled as ‘a process evaluation’ (31), a qualitative questionnaire study reported as 230 
‘informing the process evaluation’ (30), and a qualitative interview study labelled as a ‘qualitative 231 
evaluation’ (29).  However the articles indicated that the studies were interlinked, and formed a 232 
‘sequential mixed-methods study’ (31).   233 
None of the journal articles reporting process evaluation results (n=16) used the keyword “process 234 
evaluation”. 235 
Characteristics of process evaluation studies 236 
Of the 17 process evaluation studies identified nine were quantitative (22, 24-28, 32, 37, 39, 40) and 237 
eight qualitative (23, 29-31, 34-36, 38, 41, 42).  The three labelled as process evaluations were all 238 
qualitative (30, 31, 33, 34).  There were a variety of data collection methods as can be seen in table 239 
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4, with the use of trial data (n=5), interviews (n=4), and questionnaires (n=3) being most common.  240 
The reporting articles of three quantitative process evaluations (25, 27, 37) also presented detailed 241 
descriptions of trial or process evaluation methods.   242 
Twelve process evaluations evaluated only intervention processes (22, 24, 28-31, 33-36, 38-42), and 243 
five evaluated both trial and intervention processes (23, 25-27, 32, 37).  Of the latter, one explored 244 
patients’ experiences of trial participation qualitatively (23) and two described in detail the trial 245 
processes undertaken to ensure fidelity (27, 37).  One investigated the trial processes for defining 246 
the pragmatic RCT trial population, by undertaking independent assessment of the radiographs used 247 
by recruiting surgeons to determine trial inclusion (25).  Another investigated the impact of surgeon 248 
and patient treatment preferences on trial recruitment and adherence to trial follow up (32).  249 
Further details of the processes evaluated by all 17 studies can be found in table 4. 250 
Process evaluation components reported in the trial results papers and process evaluation papers 251 
All 31 pragmatic RCTs reported process data in their trial results paper(s), with a median of five 252 
different MRC process evaluation components (IQR=3; range 1-9) reported at least once per trial 253 
results paper.  Further details can be found in additional file 4. 254 
Figure 3 shows the percentages of pragmatic RCTs (n=31) reporting each MRC process evaluation 255 
component in their trial results paper(s), and the percentages of process evaluation studies (n=17) 256 
reporting each component. 257 
Figure 3: MRC process evaluation components reported in the trial results papers and process 258 
evaluations 259 
Although we found most of the identified process evaluation components to be reported in the main 260 
trial papers and/or in papers labelled process evaluations, the component ‘how delivery is achieved’ 261 
was only reported in process evaluation papers and ‘dose’ was only reported in trial results papers.  262 
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The other ‘implementation’ components – ‘fidelity’, ‘adaptations’, and ‘reach’ were more frequently 263 
reported in the trial results papers than the process evaluation papers. 264 
Additional file 4 lists the included 31 pragmatic RCT results papers, and the process evaluation 265 
components reported in each.  Additional file 5 shows the data items we mapped to each process 266 
evaluation component in the trial results papers and process evaluation papers. 267 
Barriers and facilitators to conducting process evaluations 268 
We identified three main themes of reported barriers and facilitators to conducting process 269 
evaluation within pragmatic RCTs, shown in figure 4.  These themes were: collecting complete and 270 
accurate data in health services settings; recruiting the process evaluation participants; and complex 271 
regulatory systems (only barriers identified within this theme).   272 
Figure 4: Reported barriers and facilitators 273 
Reported value of the process evaluation studies 274 
We identified three main themes relating to the reported value of the process evaluation: 1) 275 
whether the process evaluation added value to the intervention; 2) whether the process added 276 
value to the trial; or 3) whether the process evaluation’s value related to something external to the 277 
trial and intervention.  Figure 5 shows main themes and sub-themes, and table 5 shows the number 278 
of process evaluations mentioning each subtheme and examples of data relating to each subtheme.  279 
A full table of all data for each subtheme is in additional file 6. 280 
 281 
Figure 5: Synthesis of reported values of process evaluation studies 282 
Table 5: Reported value subthemes 283 
Subtheme Number of 
process 
evaluations 
reporting this 
value (n=17) 
Examples of reported values in subtheme 
15 
 
Adding to wider 
knowledge 
16 Informing future trial design (23, 25, 27, 28, 32, 33, 38) 
Improving future design of similar interventions (22, 24, 33) 
Informing post-trial 
transfer of intervention 
to practice 
15 Providing evidence of feasibility (28, 33) 
Highlighting potential disadvantages of intervention to 
facilitate consent discussions with patients (23) 
Identifying intervention 
improvements 
10 Adding stronger monitoring protocols to promote adherence 
(33) 
Recommendation to research effectiveness over time (29) 
Providing reasons for 
trial results 
8 Reasons for non-positive results (33, 38) 
Reasons for positive results (28-31, 35)  
Addressing an identified 
concern about the 
intervention 
7 Concern about effect of cognitive impairment on 
effectiveness (22) 
Concern about participant adherence (33, 35) 
Adding information not 
provided by the trial 
6 Participant and deliverer experiences and perceptions (23, 
35) 
Nuance and context (23) 
Increasing accuracy of 
trial results 
6 Investigating threats to internal validity (26) 
Accurately defining trial population (25) 
Understanding how the 
intervention works 
4 Understanding what was delivered in a flexible intervention 
(38) 
Mechanisms of impact (28) 
Building on trial data 2 Exploring findings of subgroup analysis (29) 
Understanding 
applicability of trial 
results 
2 Evaluating whether intended pragmatic trial population 
achieved (25) 
Improving usual care at 
trial sites 
1 Highlighting gaps in current care provision (27) 
Meeting pragmatic RCT 
reporting requirements 
1 Adhere to reporting standards for pragmatic and non-
pharmacological trials (27) 
Meeting 
recommendation to 
conduct process 
evaluation 
1 Following MRC recommendations (28) 
 284 
Reported value specifically relating to the pragmatic RCT 285 
The reports of three process evaluations belonging to the same trial (25-27, 32) (not labelled as 286 
process evaluations) discussed the pragmatic nature of the trial and the process evaluations’ 287 
contributions in detail.  All highlighted how they supported validity of trial results, by addressing 288 
potentially problematic areas of the pragmatic trial design.  In one process evaluation (25, 26) 289 
authors report it confirmed that the achieved trial sample was pragmatic as intended, and endorsed 290 
the pragmatic methods used to determine trial eligibility.  In another (26, 27) authors describe how 291 
it provided evidence of a good standard of, and therefore comparable, real-world clinical practice in 292 
the intervention and usual care delivered in the pragmatic trial across trial sites.  In the final process 293 
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evaluation (26, 32) the impact of patient and surgeon preference on internal and external validity is 294 
investigated, acknowledging that this is a threat to the validity of trial findings from the real-world 295 
setting. 296 
No other reports explicitly discussed the pragmatic nature of the RCT.  However one process 297 
evaluation (38) used a qualitative content analysis to ‘describe the pragmatic reality’ of intervention 298 
delivery, and its authors emphasise that this was important to allow post-trial replication of a 299 
flexible intervention with a large potential variability of delivery in a complex setting.   In the report 300 
of a qualitative interview study with intervention recipients and providers (42), authors highlight 301 
that these process evaluation data provide real-life insights to aid post-trial implementation. 302 
Accessibility of process evaluation studies 303 
Thirteen of the 17 process evaluation studies (22, 24, 28-32, 35-38, 40-42) had no mention in their 304 
corresponding index trial results papers.   305 
Journal articles reporting process evaluation results (n=16) were published a median of 15.5 months 306 
(range -3 – 42; IQR 18.25) after the corresponding index trial results papers.  None were published in 307 
the same journals as the trial results papers.  Two trials had multiple process evaluation studies 308 
published in the same journals (25, 27, 29-31).  Twelve of the 16 process evaluation journal articles  309 
(22, 28-32, 35, 37-39, 41) were not included in the trial registry entries.  A forward citation search of 310 
the index trial results paper was required to locate 9/16 of the process evaluation journal articles.  311 
Two process evaluation journal articles (37, 38) did not appear in the trial results paper, trial registry, 312 
or forwards citation searches.  These were located by chance before contacting authors as they were 313 
mentioned in other papers associated with the trials.  All process evaluation journal articles named 314 
or referenced the corresponding trial, however 9/16 did not name or explicitly link it to the trial in 315 
the title or abstract (22, 24, 25, 29-31, 39-41). 316 
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Six of the 12 trials with process evaluation(s) were funded by the UK NIHR HTA programme and 317 
published an HTA monograph (23, 26, 34, 36, 42, 48).  One process evaluation was only reported in 318 
the HTA monograph (23), not a journal article.  Six process evaluation studies were published at least 319 
in part in both a journal article (25, 27, 32, 33, 35, 41) and HTA monograph (26, 34, 36, 42).  Two 320 
process evaluations were part of HTA funded trials, however results were not reported in the HTA 321 
monographs, only in journal articles (28, 38).  322 
The five HTA monographs reporting process evaluation findings (23, 26, 34, 36, 42) all appeared in 323 
the trial registry and were published a median of 1 month (IQR 3; range 0-4) after the trial results 324 
papers.  Combining publication data for journal articles and HTA monographs therefore improved 325 
these aspects of accessibility for the whole sample of process evaluations (n=17).  If the earliest of 326 
the HTA monograph and journal article for each process evaluation is included, process evaluation 327 
studies (n=17) were published a median of five months (range 0-36; IQR 15.5) after the trial results.  328 
Similarly, 9/17 process evaluations were published in a publication included in the trial registry 329 
entry. 330 
Discussion 331 
Summary of findings 332 
We identified a range of reported benefits of process evaluations to the interventions they 333 
evaluated, to the associated pragmatic RCTs, and beyond to wider knowledge.  Nonetheless, only 334 
approximately one third (12/31) of the pragmatic RCTs included in this review had published process 335 
evaluations.  However, many data items were reported in trial results papers, which we mapped to 336 
MRC-defined process evaluation components.   Very few (3/17) studies which we categorised as 337 
process evaluations were labelled as such, and the label was used inconsistently in those which did 338 
employ it.  The 17 process evaluations utilised a variety of qualitative and quantitative methods and 339 
examined a wide range of process evaluation components, including trial processes.  We identified 340 
several practical barriers and facilitators to their design and conduct, and found visibility and 341 
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accessibility of process evaluation results were often suboptimal.  We now discuss these findings and 342 
draw recommendations, with a summary of recommendations presented in table 6. 343 
Value, inclusion, and definitions 344 
In the design and evaluation of complex interventions there is increasing recognition that process 345 
evaluations are necessary (2), and calls for their routine inclusion (1).  In support of this, we 346 
identified a wide range of ways in which process evaluations may add value to interventions and 347 
trials.  Some of the values we identified resonate with previous reviews (10, 49), such as informing 348 
post-trial implementation of interventions into practice and contributing to wider knowledge.  We 349 
also identified some less recognised, for example improving the standard of care at trial sites by 350 
exposing gaps in current care provision (27).  These findings are useful to researchers to aid 351 
reflection on the potential value of process evaluations, and articulation of this to stakeholders.  We 352 
did not investigate whether the reported value of the process evaluations related to whether or not 353 
the associated trial showed evidence of effect, however this would be useful to include in future 354 
reviews. 355 
Our findings suggest that, at least in 2015, process evaluations were far from routine in the health 356 
services research context.  Nonetheless, our mapping of process evaluation components to 357 
outcomes reported in the trial results papers suggests that process was considered, even if they did 358 
not publish a separate process evaluation paper.  This leads us to question the definition of process 359 
evaluation.  Our perception of a process evaluation is that it is more substantial than measuring a 360 
single process outcome, however when extensive process data are reported within trial results the 361 
distinction between ‘a process evaluation’ and this suite of process data is less clear.   362 
Further need for definitional clarity is demonstrated by the paucity and inconsistency of use of the 363 
label ‘process evaluation’ in the 17 separate studies.  This echoes a finding of a previous systematic 364 
review (10), which reported only 32 of 124 ‘process evaluations’ used the label – a similar proportion 365 
to the labelling in our studies.   366 
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The MRC guidance (4) states that there is no unified definition of process evaluation, and the 367 
theoretical scope laid out in process evaluation frameworks and guidance (4, 5, 8, 9) is very broad, 368 
encompassing many methods, areas of investigation, and scales of study.  This wide variety of 369 
possible characteristics of process evaluation is likely to generate confusion and may explain the 370 
inconsistent use of the label.  Furthermore, the MRC guidance (4) only discusses process evaluation 371 
of interventions, however in common with other authors (5, 50-53) we identified the important role 372 
for process evaluation in evaluating trial processes, such as recruitment and patient experience of 373 
trial participation.  We therefore believe simply repeating previous calls for clearer labelling (5) is 374 
insufficient and recommend further discussion about the meaning of the term ‘process evaluation’. 375 
Barriers and facilitators  376 
We identified several barriers and facilitators to process evaluation researchers collecting optimal 377 
data, recruiting participants, and working within regulatory frameworks in the real-world health 378 
service contexts in which pragmatic RCTs operate.  Several of these identified challenges and 379 
enablers are not addressed in the MRC guidance (4), however a previous systematic review (10) 380 
recommended monitoring and reporting process evaluation recruitment.  We recommend 381 
researchers continue to share their experiences of challenges and successful strategies for 382 
conducting process evaluations in this context. 383 
Indexing and visibility 384 
Process evaluations often had poor visibility through not being mentioned in trial results papers, 385 
and/or not included in trial registries.  Furthermore, time delay to publication, not naming trials in 386 
titles or abstracts, and not labelling or indexing as process evaluations were significant barriers to 387 
locating articles in citation searches.  Reporting guidance for process evaluations is available (4, 5), 388 
emphasising the importance of linking outcome and process evaluation papers.  Our findings 389 
demonstrate the importance of following these recommendations, specifically that outcome results 390 
journal articles should mention that a process evaluation was undertaken, and process evaluation 391 
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journal articles should name or explicitly link to the trial in their title or abstract.  We additionally 392 
recommend process evaluation articles are included in trial registries, and that mention of any 393 
process evaluation undertaken could usefully be added to relevant CONSORT trial reporting 394 
checklists (54, 55).  We also highlight that some HTA monographs reported process evaluations 395 
alongside trial outcomes and integrated discussion of findings (23, 26, 34, 36, 42), and therefore 396 
demonstrate a useful reporting format.   397 
Table 6: Summary of recommendations 398 
Recommendations for process 
evaluation design 
 Consider the identified potential values of process 
evaluation within pragmatic RCTs and how these may 
be realised and articulated to stakeholders 
 We encourage debate about the meaning of the label 
‘process evaluation’ and how it may be more 
consistently applied 
Recommendations for process 
evaluation conduct 
 Consider the identified barriers and facilitators and 
how to address these when conducting process 
evaluations in health services settings 
Recommendations for process 
evaluation dissemination 
 Ensure process evaluation publications are included in 
the trial registry entry 
 Ensure process evaluations are mentioned in journal 
articles reporting the parent trial, and consider adding 
this item to relevant CONSORT checklists 
 Ensure process evaluation publications name or refer 
to the parent trial in the title or abstract 
 Publish strategies for conducting successful process 
evaluations and addressing challenges in health 
services settings, such as to recruiting process 
evaluation participants and collecting data 
 399 
Strengths and limitations 400 
The key design strength of this review was using an index sample of pragmatic RCTs, then identifying 401 
any reported ‘process evaluation’ using an operational definition.  This provided valuable 402 
information on process evaluation frequency and accessibility, and highlighted inconsistency of use 403 
of the ‘process evaluation’ label.  However, a limitation is that we could include only a sample of 404 
pragmatic RCTs.  Limiting to trials published in MEDLINE Core Clinical Journals means findings are 405 
likely reflective of well-funded health services research trials but may not be representative of trials 406 
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published elsewhere.  We also only included RCTs described as ‘pragmatic’ in the title or abstract.  407 
As such labelling is not an essential reporting criterion for pragmatic RCTs (54), trials were not 408 
identified for inclusion if they only used the term ‘pragmatic’ elsewhere in the paper.   409 
Limiting index trial inclusion to publication in 2015 ensured a reasonable length of time for 410 
publication of process evaluation papers, and indeed two process evaluations were published in 411 
2019.  However, this also means findings may not be representative of process evaluations being 412 
designed and conducted now.  Our findings can therefore only highlight potential areas of 413 
uncertainty, difficulty, or opportunity, with alternative research approaches such as surveys or 414 
interviews needed to examine current practice.  We also acknowledge as a limitation that we used 415 
the MRC process evaluation framework to identify and describe process evaluations, when most 416 
process evaluations in our sample (associated with trials published in 2015) would very likely have 417 
been designed prior to publication of the MRC guidance (4).  418 
The search methods for identifying associated publications were comprehensive, with a good 419 
response rate from authors.  We used a robust process for deciding which publications to categorise 420 
as process evaluations, and the team included highly experienced health service researchers with 421 
experience of designing and conducting process evaluations.  We acknowledge others may disagree 422 
with our operational definition and categorisations, however highlight this ambiguity is itself an 423 
important finding.  424 
Double data extraction was carried out on fields we considered to be subjective, increasing the 425 
reliability of findings.  There are currently no agreed quality assessment standards for process 426 
evaluations (4) and therefore we did not appraise the quality of included studies, however doing so 427 
would add to and strengthen the findings. 428 
 429 
Conclusion 430 
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This review provides valuable insight into the frequency and characteristics of process evaluations, 431 
within a sample of systematically identified index pragmatic RCTs published in a single year, and 432 
highlights challenges and enablers to their practical conduct in health services settings.  Significantly, 433 
it suggests that the definition of process evaluation is inconsistent, and that the meaning of the term 434 
requires clarification.  Despite the wide range of identified values of process evaluations this review 435 
highlights important problems with accessibility, which are likely barriers to fully realising this value.  436 
Often process evaluations are invisible in pragmatic RCT reporting, and we therefore make several 437 
straightforward but significant reporting recommendations.   438 
 439 
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Table 4 
Reference(s) Description of process evaluation Methodology and data 
collection methods 
Intervention or 
trial processes 
Process evaluation components 
 
 
Labelled 
as process 
evaluation 
Ball 2018 (22) 
 
 
Investigated effect of mild cognitive 
impairment in participants on 
intervention outcome 
Quantitative, 
Trial dataset 
Intervention  Contextual moderators No  
Clark 2015 (23) 
 
 
Explored patient perceptions of 
acceptability of intervention in both 
groups, and motivations for agreeing 
or refusing to participate in the trial 
Qualitative, 
Interviews  
Intervention 
and trial 
Participant responses 
 
Reach 
 
Contextual moderators 
 
Unintended consequences 
 
Causal mechanisms in context 
No  
Grubbs 2015 
(24) 
 
 
Investigated which factors predicted 
patient uptake of an element of the 
intervention found to mediate the 
primary outcome 
Quantitative, 
Medical record review 
Intervention  Contextual moderators No  
Handoll 2016 
(25) 
 
Handoll 2015 
(26) 
 
Described how the intended fracture 
population was practically achieved in 
pragmatic RCT, including results of 
formal independent assessment and 
classification of trial fractures 
Quantitative, 
Detailed author 
description,  
Trial dataset 
Intervention 
and trial 
Reach No  
Handoll 2014 
(27) 
 
Handoll 2015 
(26) 
 
Described processes undertaken to 
ensure usual care received by both 
groups in trial was good quality and 
comparable, including results of 
methods described 
Quantitative, 
Detailed author 
description, 
Deliverer self-report 
 
Intervention 
and trial 
How delivery is achieved 
 
Fidelity 
No  
Hall 2017 (28) 
 
 
Investigated mediators of intervention 
outcome 
Quantitative, 
Trial dataset 
Intervention  Mediators  No  
Hill 2016 (29) 
 
 
Explored perceptions of ward staff 
about how intervention contributed to 
outcome, and experience of 
Qualitative, 
Focus groups  
 
Intervention How delivery is achieved 
 
Participant responses 
 
Contextual moderators 
 
No  
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Reference(s) Description of process evaluation Methodology and data 
collection methods 
Intervention or 
trial processes 
Process evaluation components 
 
 
Labelled 
as process 
evaluation 
intervention being delivered on their 
ward 
 Causal mechanisms in context 
 
Contextual factors shaping intervention theory 
Hill 2016 (30) 
 
 
Explored patient experiences of 
intervention and perceived barriers to 
engagement 
Qualitative, 
Semi-structured 
questionnaires 
Intervention Participant responses 
 
Causal mechanisms in context 
 
Contextual factors shaping intervention theory 
Yes 
Hill 2015 (31) 
 
 
Explored perceptions of intervention 
deliverers of delivering intervention 
and how the intervention worked 
Qualitative, 
Focus groups, interview, 
field notes, intervention 
notes 
Intervention How delivery is achieved 
 
Contextual factors shaping intervention theory 
 
Participant responses 
 
Causal mechanisms in context 
Yes  
Keding 2019 
(32) 
 
Handoll 2015 
(26) 
 
Explored how patient and surgeon 
treatment preferences impacted 
recruitment, trial conduct, and patient 
outcomes 
Quantitative, 
Trial dataset 
Intervention 
and trial 
Reach 
 
Participant responses 
 
Contextual moderators 
No 
Knowles 2015 
(33) 
 
Littlewood 2015 
(34) 
 
Explored patient experiences of the 
intervention, including acceptability, 
ease of use, barriers to engagement, 
content, accessibility, and support.  
Also explored healthcare professional 
perceptions of feasibility and which 
patients intervention most suited to. 
Qualitative, 
Interviews 
Intervention Participant responses 
 
How delivery is achieved 
 
Reach 
 
Causal mechanisms in context 
 
Contextual moderators 
 
Unintended consequences 
 
Contextual factors shaping intervention theory 
Yes 
 
 
Nichols 2017 
(35) 
 
Williams 2015 
(36) 
 
Explored experiences of patients 
about intervention, with focus on 
patient adherence, and how changed 
over time 
Qualitative, 
Interviews (longitudinal) 
Intervention Participant responses 
 
Causal mechanisms in context 
 
Contextual moderators 
 
How delivery is achieved 
 
No  
Novak 2015 (37) 
 
Investigated whether and how trial 
sites supplied thawed plasma in a 
timely manner  
Quantitative, 
Detailed author 
description, 
Intervention 
and trial 
Fidelity 
 
How delivery is achieved 
No  
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Reference(s) Description of process evaluation Methodology and data 
collection methods 
Intervention or 
trial processes 
Process evaluation components 
 
 
Labelled 
as process 
evaluation 
Observation, reports 
from sites 
Sands 2016 (38) 
 
Explored how the flexible complex 
intervention was delivered in real-
world complex settings 
Qualitative, 
Trial dataset 
Intervention How delivery is achieved 
 
Adaptations 
 
Contextual moderators 
 
Participant responses 
 
Unintended consequences 
 
Contextual factors shaping intervention theory 
 
Fidelity 
No 
Saville 2016 (39) Explored preferences and experiences 
of intervention deliverers about 
various aspects of intervention 
Quantitative, 
Questionnaire   
Intervention How delivery is achieved No  
Tjia 2017 (40) 
 
Investigated patients’ perceptions of 
benefits and drawbacks of 
intervention 
Quantitative, 
Questionnaire   
Intervention Participant responses No  
Vennik 2019 
(41) 
 
Williamson 
2016 (42) 
 
Explored views and experiences of 
parents and practice nurses of 
intervention and usual care 
Qualitative, 
Interviews 
Intervention Participant responses 
 
How delivery is achieved 
 
Contextual factors shaping intervention theory 
 
Causal mechanisms in context 
 
Unintended consequences 
No  
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Additional file 1 
MEDLINE (Ovid) search strategy 
Search conducted via Ovid (MEDLINE)® and EPub Ahead of Print In-Process & Other Non-Indexed 
Citations, Daily and Versions®  
1. (pragmatic and trial).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier, synonyms] 
2. limit 1 to (english language and humans and "core clinical journals (aim)" and yr="2015" and 
(clinical trial, all or clinical trial or controlled clinical trial or pragmatic clinical trial or 
randomized controlled trial)) 
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Additional file 2 - trial descriptor data fields 
Data field Operationalisation Extract from Extract as 
Funder Who funded the trial Trial results paper, or trial 
registry if not stated 
Free text 
Publication 
month 
Month the trial results paper was published in print, or online for online 
only journals 
Medline search result Month 
Publication year Year the trial results paper was published in print, or online for online 
only journals 
Medline search result 2015 
Country The country / countries the intervention was delivered in during the trial Trial results paper Country 
Journal The journal the trial results paper was published in Trial results paper Journal name 
Intervention Brief description of intervention(s) Trial results paper Free text 
Comparator What was received by the control / comparator group(s) Trial results paper Free text 
Intervention 
recipients 
Who received the intervention Trial results paper Free text 
Intervention 
deliverer 
Who administered / delivered the intervention(s) during the trial Trial results paper Free text 
Clinical specialty The clinical field the intervention was intended for Trial results paper  Free text 
Setting The setting of intervention delivery. Trial results paper  Free text 
Randomisation 
level 
Whether participants were individually or cluster randomised Trial results paper Individual 
Cluster 
Primary 
outcome result 
Whether the primary outcome result was stated as being statistically 
significant in the abstract of the paper (p value or confidence interval) 
 
 
Trial results paper – 
abstract 
If not clear from abstract 
class as unclear 
If classification does not fit 
e.g. non-inferiority, 
multiple outcomes, class 
as n/a 
Positive 
Not positive 
n/a if does not fit 
Trial design  Further details of the trial design Trial results paper 2-arm 
3-arm 
Non-inferiority 
Stepped-wedge 
Crossover  
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Additional file 3 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
2-3 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3-5 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
5 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
3 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
6-7 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
6-7 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
6 (Add. 
file 1) 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
6-8 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
7-9 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
8-9 (add. 
File 2) 
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Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
n/a 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  n/a 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis.  
8-9 
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Additional file 4 - included pragmatic RCTs 
  MRC process evaluation components reported in index trial results 
paper(s) 
 
Reference of index 
trial results paper 
Journal 
Country 
Further references* 
Intervention Reach 
Fidelity 
D
ose 
 H
ow
 delivery is 
achieved 
A
daptations 
Contextual 
m
oderators 
Contextual factors 
that shape 
intervention theory  
 Causal m
echanism
s 
that m
aintain status 
quo or enhance 
effects 
M
ediators 
U
nanticipated 
pathw
ays and 
consequences 
Participant 
responses 
Separate process 
evaluation paper(s) 
Bartels 2015 (1)  
American Journal of 
Psychiatry 
USA 
 
Health promotion coaching 
for obesity in serious mental 
illness 
Y     Y Y Y Y  Y No (included process 
evaluation but using 
data from multiple 
trials so excluded from 
review) 
Bender 2015 (2) 
JAMA Pediatrics 
USA 
Speech recognition 
telephone calls to improve 
adherence to child asthma 
treatment 
Y     Y Y    Y No  
Boulvain 2015 (3) 
Lancet 
France, Belgium, 
Switzerland 
Induction of labour vs 
expectant management for 
large-for-date foetuses 
Y           No  
Cooper 2015 (4) 
BMJ 
UK 
Clark 2015 (5) 
Outpatient vs inpatient 
uterine polyp treatment  
Y     Y  Y  Y Y Yes 
 
Curtis 2015 (6) 
Canadian Medical 
Association Journal 
Canada 
Ultrasound or near-infrared 
vascular imaging to guide 
peripheral intravenous 
catheterisation  
Y     Y Y     No  
El-Khoury 2015 (7) 
BMJ 
France 
Balance training to prevent 
fall-induced injuries 
Y  Y       Y Y No 
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  MRC process evaluation components reported in index trial results 
paper(s) 
 
Reference of index 
trial results paper 
Journal 
Country 
Further references* 
Intervention Reach 
Fidelity 
D
ose 
 H
ow
 delivery is 
achieved 
A
daptations 
Contextual 
m
oderators 
Contextual factors 
that shape 
intervention theory  
 Causal m
echanism
s 
that m
aintain status 
quo or enhance 
effects 
M
ediators 
U
nanticipated 
pathw
ays and 
consequences 
Participant 
responses 
Separate process 
evaluation paper(s) 
Fortney 2015 (8) 
JAMA Psychiatry 
USA 
Telemedicine-based 
collaborative care for 
veterans with PTSD 
Y Y Y  Y    Y  Y Yes  
Gilbody 2015 (9) 
BMJ 
UK 
Littlewood 2015 (10) 
Computerised cognitive 
behavioural therapy for 
depression 
Y     Y  Y   Y Y Yes  
Hill 2015 (11) 
Lancet 
Australia 
Individualised falls-
prevention education for 
hospital patients, with 
training and feedback for 
staff  
Y Y Y   Y Y   Y Y Yes  
Holcomb 2015 (12) 
JAMA 
North America 
Baraniuk 2014 (13) 
Zhu 2016 (14) 
Comparison of 2 different 
ratios of blood products in 
patients with major trauma 
Y Y   Y       Yes  
Honkoop 2015 (15) 
Journal of Allergy and 
Clinical Immunology 
Netherlands 
Comparison of 3 treatment 
strategies targeting 
different levels of asthma 
control 
Y Y         Y No  
Hui 2015 (16) 
Gut 
Hong Kong 
Comparison of medical and 
nurse endoscopists 
performing colonoscopy 
Y    Y Y     Y No  
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  MRC process evaluation components reported in index trial results 
paper(s) 
 
Reference of index 
trial results paper 
Journal 
Country 
Further references* 
Intervention Reach 
Fidelity 
D
ose 
 H
ow
 delivery is 
achieved 
A
daptations 
Contextual 
m
oderators 
Contextual factors 
that shape 
intervention theory  
 Causal m
echanism
s 
that m
aintain status 
quo or enhance 
effects 
M
ediators 
U
nanticipated 
pathw
ays and 
consequences 
Participant 
responses 
Separate process 
evaluation paper(s) 
Kempe 2015 (17) 
JAMA Pediatrics 
USA 
Collaborative centralised 
reminder/recall system to 
increase immunisation rates 
in young children 
Y    Y  Y   Y  Yes  
Knowles 2015 (18) 
Lancet 
UK  
Horrocks 2015 (19) 
Percutaneous tibial nerve 
stimulation for treatment of 
faecal incontinence 
 
Y Y    Y    Y Y No  
Kutner 2015 (20) 
JAMA Internal 
Medicine 
USA 
Statin discontinuation in 
advanced life-limiting illness 
Y         Y Y Yes  
Lamb 2015 (21) 
Lancet 
UK 
Williams 2015 (22) 
Exercises to improve hand 
function in rheumatoid 
arthritis 
Y Y Y  Y Y Y Y  Y Y Yes  
Moreira 2015 (23) 
Nursing Research 
Brazil 
Nursing case management 
for patients with type 2 
diabetes 
Y     Y  Y    No  
Moseley 2015 (24) 
JAMA 
Australia 
Exercise programme for 
rehabilitation following 
ankle fracture 
Y Y    Y  Y  Y Y No  
Mouncey 2015a (25) 
NEJM 
UK  
Mouncey 2015b (26) 
Early, Goal-Directed 
Resuscitation protocol for 
septic shock 
 
Y Y   Y Y Y Y  Y  No  
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  MRC process evaluation components reported in index trial results 
paper(s) 
 
Reference of index 
trial results paper 
Journal 
Country 
Further references* 
Intervention Reach 
Fidelity 
D
ose 
 H
ow
 delivery is 
achieved 
A
daptations 
Contextual 
m
oderators 
Contextual factors 
that shape 
intervention theory  
 Causal m
echanism
s 
that m
aintain status 
quo or enhance 
effects 
M
ediators 
U
nanticipated 
pathw
ays and 
consequences 
Participant 
responses 
Separate process 
evaluation paper(s) 
Noto 2015 (27) 
JAMA 
USA 
Chlorhexadine bathing in 
intensive care units 
Y Y    Y      No  
Perkins 2015 (28) 
Lancet 
UK 
Gates 2017 (29) 
Mechanical vs manual chest 
compression for out of 
hospital cardiac arrest 
Y Y    Y  Y  Y  No  
Rangan 2015 (30) 
JAMA 
UK 
Handoll 2015 (31) 
Surgical vs non-surgical 
treatment for adults with 
displaced fracture of 
proximal humerus  
Y Y   Y Y  Y  Y Y Yes  
Sackley 2015 (32) 
BMJ 
UK 
Sackley 2016 (33) 
Occupational therapy for 
care home residents with 
stroke disability 
Y  Y   Y Y   Y  Yes 
Scott 2015 (34) 
BMJ 
UK 
Scott 2014 (35) 
Tumour necrosis factor 
inhibitors versus 
combination intensive 
therapy with conventional 
disease modifying anti-
rheumatic drugs 
Y    Y  Y   Y Y No  
Semler 2015 (36) 
Critical Care Medicine 
USA 
Electronic sepsis evaluation 
and management tool in 
intensive care 
Y  Y  Y Y     Y No  
Smith 2015a (37) 
BMJ 
UK 
Patient-controlled analgesia 
for patients in emergency 
Y         Y Y No  
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  MRC process evaluation components reported in index trial results 
paper(s) 
 
Reference of index 
trial results paper 
Journal 
Country 
Further references* 
Intervention Reach 
Fidelity 
D
ose 
 H
ow
 delivery is 
achieved 
A
daptations 
Contextual 
m
oderators 
Contextual factors 
that shape 
intervention theory  
 Causal m
echanism
s 
that m
aintain status 
quo or enhance 
effects 
M
ediators 
U
nanticipated 
pathw
ays and 
consequences 
Participant 
responses 
Separate process 
evaluation paper(s) 
department with pain from 
traumatic injuries 
Smith 2015b (38) 
BMJ 
UK 
Patient-controlled analgesia 
for patients in emergency 
department with pain from 
non-traumatic abdominal 
injuries 
Y         Y Y No  
Stewart 2015 (39) 
Lancet 
Australia  
Standard vs atrial-fibrillation 
specific management 
strategy 
Y Y Y  Y   Y    Yes  
Wechsler 2015 (40) 
JAMA 
USA 
Anticholinergic vs long-
acting β-agonist in 
combination with inhaled 
corticosteroids in black 
adults with asthma 
Y    Y Y    Y Y No  
Westendorp 2015 (41) 
Lancet  
Netherlands  
Preventive antibiotics in 
stroke 
Y  Y   Y Y Y  Y  No  
Williamson 2015 (42) 
Canadian Medical 
Association Journal 
UK 
Williamson 2015 (43) 
Nasal balloon autoinflation 
in children with otitis media 
with effusion in primary 
care 
Y     Y  Y  Y Y Yes 
 
*If applicable - references of additional publications reporting trial results from which we extracted data on process evaluation components 
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Additional file 5 
Items mapped to each process evaluation component 
MRC component Included items 
Implementation 
Adaptations 
Alterations made 
to an intervention 
in order to achieve 
better contextual 
fit 
 
Trial papers 
 Time taken to deliver interventions where this was not specified by a protocol 
 Means through which the intervention was delivered where this was flexible, e.g. qualifications of staff delivering the 
intervention 
 Which intervention components were delivered to participants as part of flexible interventions 
 Description of alternative materials used by sites to trial materials 
 
Process evaluation papers 
 Description of how a flexible intervention was delivered in practice 
Dose 
How much 
intervention is 
delivered 
 
Trial papers 
 Numbers of intervention sessions delivered to participants  
 Numbers of ‘occurrences’ of optional intervention components delivered to participants 
 Numbers of times the intervention electronic tool was opened  
 Time spent by deliverers on intervention components 
Fidelity 
The consistency of 
what is 
implemented with 
the planned 
intervention 
 
Trial papers 
 Whether or not intervention components were delivered 
 The quality or standard of (components of) interventions delivered  
 Reasons for non-adherence or protocol deviations 
 Fidelity scores, adherence percentages  
 Whether or not the correct randomised intervention was delivered  
 Analyses to examine the effect of non-fidelity on the primary outcome – e.g. per-protocol, complier average causal effect 
analyses  
 
Process evaluation papers 
 Whether and how centres delivered interventions in accordance with intervention protocols 
How delivery is 
achieved 
Process evaluation papers 
 Qualitative exploration of perceptions of intervention deliverers 
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MRC component Included items 
The structures, 
resources and 
mechanisms 
through which 
delivery is achieved 
 
 Measures taken to ensure fidelity to intervention and usual care protocols 
Reach 
Extent to which 
target audience 
comes into contact 
with intervention 
 
 
Trial papers 
 Trial flow diagrams / CONSORT diagrams 
 Reasons for non-participation, exclusion, drop-out  
 Participant and site characteristics 
 Numbers of participants recruited from different sites  
 Numbers of participants who received the randomised intervention  
 Comparison of demographics between those who declined participation and trial participants 
 Characteristics of screened but not randomised patients  
 Reach of interventions delivered to randomised populations  
 Comparison of demographics between participants completing and not completing follow-up  
 Comparison of site characteristics with all departments in the country  
 Comparison of participant characteristics with national patient population  
 Length of time sites open to recruitment, length of time between obtaining site NHS permission and opening to 
recruitment  
 Independent rating of reasons for patients being judged ineligible by sites  
 Subgroup analysis comparing outcomes between patients randomised to receive the intervention who answered and did 
not answer at least one call. 
 Sample attrition bias  
 Sensitivity analysis of primary outcome including participants with missing outcomes  
 Sensitivity analysis excluding participants from 2 poorly recruiting centres  
 Associations between participant characteristics and the completeness of response to providing follow-up data 
 
Process evaluation papers 
 Interviews with healthcare professionals about the degree to which they targeted recruitment to patients deemed most 
suitable, and perceptions about which patients were most suitable for the intervention.  
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MRC component Included items 
 Patient motivations for agreeing or declining trial participation 
 Measures taken to ensure inclusion of intended trial population in pragmatic trial 
 
Context 
Causal 
mechanisms that 
act to maintain the 
status quo, or 
enhance effects 
Trial papers 
 Details of usual care received by participants  
 Use of similar interventions by usual care group, impact of use on outcomes 
 Change in medication use by trial participants during the intervention period  
 Impact of concurrent interventions  
 Seasonal effects 
 
Process evaluation papers 
 Participant reported barriers and facilitators to engaging with or adhering to the intervention 
Contextual factors 
that shape theory 
of how the 
intervention works 
Trial papers 
 Effect of time on effectiveness of the intervention – e.g. cumulative unit level effect of intervention, learning curve 
effects 
 Effect of intervention variables e.g. phone calls by answering machine or in person 
 Ceiling effect of intervention depending on participant baseline level of disability  
 Comparison of outcomes between participants who kept taking same regime and those who switched partway through 
 
Process evaluation papers 
 Qualitative findings discussing potential factors influencing intervention outcomes e.g. skills, experience, personalities 
and abilities of intervention deliverers  
Contextual 
moderators 
Shape, and may be 
shaped by, 
implementation, 
intervention 
mechanisms, and 
outcomes 
Trial papers 
 Analyses of effect of moderators on outcomes, e.g. participant age, gender, smoking status, cognition, treatment 
preferences, site characteristics 
 
Process evaluation papers 
 In qualitative studies – findings about factors which could potentially modify intervention effect 
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MRC component Included items 
 
Mechanisms of impact 
Mediators 
Intermediate 
processes which 
explain subsequent 
changes in 
outcome 
 
Trial papers 
 Effect of participant usage of different intervention components on primary outcome 
 
Process evaluation papers 
 Mediation analysis of proximal intervention effects 
Participant 
responses  
How participants 
interact with a 
complex 
intervention 
 
Trial papers 
 Uptake and use of the intervention, or components of the intervention, by trial participants, e.g. number of sessions 
attended  
 Analyses to examine the effect of adherence to or completion of an intervention or its components on the primary 
outcome 
 Subgroup analyses to investigate the effect of certain participant characteristics on level compliance with intervention 
 Participant satisfaction with treatment  
 Participant perceptions of which treatment they had received, treatment preferences at end of trial 
 Procedure acceptability to participants 
 Process-of-care outcome e.g. medication adherence, accessing therapies  
 
Process evaluation papers 
 Qualitative research exploring patient adherence, perceptions, experiences of interventions 
 Quantitative questionnaire about participant perceptions of the benefits and harms of the intervention 
 
Unintended 
pathways and 
consequences 
Trial papers 
 Participant adverse events 
 
Process evaluation papers 
 Qualitative findings included reports of unanticipated consequences 
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Additional file 6  
All extracted values of process evaluation 
Value category with details Process evaluations reporting this 
value (n=17) 
Adding value to the intervention 
 
Supporting implementation of the intervention into practice 
 Targeting or tailoring the intervention to specific patients 
 Aiding replication of a complex intervention 
 Understanding how patients engage with the intervention 
 Understanding providers’ viewpoints and willingness to collaborate 
 Developing tools / strategies for implementation 
 Targeting the intervention to specific groups  
 Highlighting important components of the intervention to implementers 
 Highlighting benefits of the intervention to promote uptake  
 Highlighting effective delivery strategies  
 Providing evidence of feasibility / acceptability  
 Tailoring delivery to different groups  
 Highlighting importance of roles of different people / agencies in ensuring successful delivery  
 Addressing barriers to implementation or uptake of the intervention  
 Recommendations for training or support to participants or deliverers  
 Suggesting how intervention could fit into existing care pathways  
 Highlighting potential disadvantages of the intervention  
 Recommendations for information to give to patients considering intervention  
 Recommendations for clinicians to help decide between interventions 
 Recommendations for further intervention implementation research 
 Highlighting lack of equipoise in deliverers 
15 
Improving the intervention 
Recommendations for further development of the intervention based on process evaluation findings: 
 Recommendations to keep all components of the intervention 
 Adding stronger monitoring protocols to promote adherence  
 Adaptations to design for patients with reduced cognition 
Recommendations for further research relating to the intervention: 
10 
54 
 
Value category with details Process evaluations reporting this 
value (n=17) 
 Effectiveness over time  
 Effectiveness in different contexts  
 Different modes of delivery e.g. group settings  
 Intervention refinement, e.g. to improve patient experience 
Addressing a concern identified about the intervention 
 Acceptability of the intervention to patients / deliverers 
 Participant adherence 
 Complexity of intervention delivery  
 Influence of participant cognition on intervention effectiveness  
7 
Understanding how the intervention works 
 Intervention mechanisms 
 Content delivered in a flexible intervention 
4 
Adding value to the RCT 
 
Providing reasons for trial results 
 Possible reasons for non-positive trial results 
 Explanations for positive trial results 
 Explanations for other trial data 
8 
Adding information not provided by the trial 
 Participant or deliverer concerns  
 Key components of intervention  
 Added clarification, nuance, context 
 Perspectives of participants after time for reflection  
 Concurrent treatments received by trial participants 
 Experiences and perceptions – things important to participants, minority views 
 
6 
Increasing accuracy of trial results 
 Assessing comparability of standard care between both randomised groups 
 Qualitative findings helping confirm quantitative data on satisfaction 
 Avoid survivor bias  
 Accurately define the trial population and facilitate purpose and interpretation of trial 
 Investigating threats to internal and external validity 
6 
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Value category with details Process evaluations reporting this 
value (n=17) 
 
Building on trial data 
 Explore findings from a subgroup analysis conducted in the main trial  
 Expand on the quantitative questionnaire data collected in the main trial about participant 
acceptability and satisfaction 
 Identified adverse events not reported in the main trial data collection 
3 
Understanding the applicability of trial results 
 Evaluating whether the intended pragmatic trial population was achieved in the trial 
 Investigating threats to external validity from patient or provider treatment preference 
2 
Meeting trial reporting requirements 
 Meeting CONSORT requirements for pragmatic and nonpharmacologic trials 
1 
Meeting recommendation to conduct process evaluation 
 Citing recommendation by MRC process evaluation framework to conduct mediation analysis 
1 
Explaining issues with trial conduct 
 Reasons for requiring recruitment extension 
1 
 
Adding value external to the intervention or RCT 
 
Contributing to wider knowledge 
 Future trial design 
 Understanding patient populations and patient experiences  
 Understanding the problem addressed by the intervention  
 Improving clinical practice in the field  
 Informing design of similar interventions  
 Highlighting that findings supported or refuted the existing knowledge base  
 Methodological recommendations 
16 
Improving usual care at trial sites 
 Highlighting gaps in current care provision 
1 
 
 
